Authored & revised by Pulathi Senaratna(Founder & Senior Editor) · Updated 7 Nov 2026
✓ Clinically reviewed by Medipaedia Editorial Board on 7 Nov 2026mID 10048
⚡ At-a-Glance Clinical Summary Card
ICD-10: A97.2ICD-11: 1D2Z
⚡ High-Yield Clinical Summary
Dengue haemorrhagic fever and dengue shock syndrome represent severe manifestations of mosquito-borne flavivirus infection characterized by acute vascular endothelial dysfunction, plasma leakage, and profound thrombocytopenia. Diagnosis relies on early NS1 antigen detection followed by serology and serial haematocrit monitoring, while first-line management mandates careful, protocolized isotonic crystalloid resuscitation to avoid fluid overload.
🩺 Specialty:
Infectious Diseases
🎯 Classic Triad / Hallmark Presentation:
Defervescence critical phase (Days 3–7): High fever with retro-orbital headache/myalgia + Progressive thrombocytopenia (<100 × 10⁹/L) with rising haematocrit (≥20% haemoconcentration from plasma leakage) + Narrow pulse pressure (≤20 mmHg) / pleural effusion / ascites
🔬 Gold-Standard Diagnostic Test:
Dengue NS1 Antigen ELISA/Rapid Test (Days 1–5) + Dengue IgM/IgG MAC-ELISA (Day ≥5) + Serial hourly Haematocrit (PCV) and Platelet monitoring
💊 First-Line Treatment Protocol:
Protocolized judicious isotonic crystalloid titration (0.9% NaCl / Ringer's Lactate guided by hourly urine output 0.5–1 mL/kg/h and serial haematocrit; rescue colloid/blood transfusion if refractory shock; strictly avoid NSAIDs/Aspirin)
Dengue haemorrhagic fever and dengue shock syndrome represent the severe, potentially life-threatening spectrum of dengue virus infection, driven by immune-mediated endothelial dysfunction and acute capillary leakage1, 2. Transmitted primarily by Aedes aegypti mosquitoes, the disease pathobiology is characterized by sudden high-grade viremia, systemic inflammation, profound thrombocytopenia, and significant plasma loss into extravascular compartments4, 5. Without prompt recognition and tailored fluid management, rapid hemodynamic collapse ensues6, 7.
1. Etiology & Risk Factors
Viral Etiology: Caused by any of the four distinct serotypes of dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4), which are single-stranded RNA viruses belonging to the family Flaviviridae4.
Secondary Heterotypic Infection: Infection with one serotype confers lifelong immunity to that specific serotype but only temporary cross-protection against others. Secondary infection with a heterotypic serotype is the primary risk factor for severe disease due to antibody-dependent enhancement (ADE)4, 5.
Host Genetic Factors: Human leukocyte antigen (HLA) polymorphisms and genetic variations in cytokine expression pathways significantly modulate individual susceptibility to severe manifestations4, 6.
Age and Immune Status: Infants experiencing primary infection via maternal antibody waning and older children or adults undergoing secondary infection are at markedly elevated risk for vascular leakage syndromes1, 6.
2. Pathophysiology
The pathophysiological hallmark of severe dengue is transient vascular dysfunction rather than fixed structural vasculitis. During secondary infection, pre-existing non-neutralizing cross-reactive antibodies bind to the incoming viral envelope proteins, forming virus-antibody complexes that efficiently infect Fc gamma receptor-bearing cells such as monocytes and macrophages5. This phenomenon, known as antibody-dependent enhancement (ADE), leads to significantly higher intracellular viral loads and rapid activation of memory T lymphocytes5. Activated T cells and infected monocytes release a massive surge of inflammatory cytokines and chemical mediators—including tumor necrosis factor-alpha (TNF-$\alpha$), interleukins (IL-2, IL-6, IL-8), and interferon-gamma—along with platelet-activating factor and complement components5, 7. This cytokine cascade induces reversible endothelial glycocalyx degradation and tight-junction disruption, precipitating sudden plasma leakage into the pleural, peritoneal, and interstitial spaces4, 6. Concurrently, bone marrow suppression and peripheral destruction drive severe thrombocytopenia, while consumptive coagulopathy and transient hepatic dysfunction contribute to bleeding diatheses1.
3. Clinical Presentation & Classic Clinical Signs
History & Cardinal Symptoms: The clinical course progresses through three distinct phases: febrile, critical, and recovery6. The febrile phase features sudden high-grade continuous fever lasting 2 to 7 days accompanied by severe frontal or retro-orbital headache, generalized myalgias, arthralgias ("breakbone fever"), maculopapular rash, and mild hemorrhagic manifestations such as positive tourniquet test or petechiae6.
Physical Examination & Named Clinical Signs: The critical phase manifests around defervescence (Days 3–7) when body temperature normalizes or drops subnormal; this is the high-risk window for sudden deterioration1, 6. Clinical evaluation reveals signs of plasma leakage including pleural effusions, ascites, and dependent edema. Hemodynamic compromise is signaled by tachycardia, cold clammy extremities, delayed capillary refill time (>2 seconds), and a narrow pulse pressure (≤20 mmHg) resulting from rising diastolic blood pressure secondary to intense vasoconstriction1, 6. Overt dengue shock syndrome occurs when blood pressure falls below the fifth percentile for age, accompanied by unmeasurable or absent peripheral pulses.
Dengue NS1 Antigen ELISA or Rapid Diagnostic Test positive during the first 1 to 5 days of symptom onset; Dengue-specific IgM and IgG capture ELISA (MAC-ELISA) positive from day 5 onward to confirm acute secondary or primary infection.
Laboratory Panel
Progressive thrombocytopenia (platelet count <100 $\times$ 10⁹/L) accompanied by hemoconcentration, demonstrated by a rise in haematocrit (PCV) $\ge$20% above baseline population or age-matched normal values. Leukopenia is frequently observed early in the febrile phase. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are typically elevated, often with AST exceeding ALT. Serum albumin and total protein drop due to capillary protein-losing leak.
Imaging / Radiology (X-ray, US, CT, MRI)
Chest radiography reveals bilateral or right-sided pleural effusions. Point-of-care ultrasound (POCUS) demonstrates gallbladder wall thickening (edema), pericholecystic fluid, and moderate-to-severe ascites, serving as highly sensitive bedside indicators of active plasma leakage.
ECG / Histopathology / Procedural
Electrocardiogram may show sinus tachycardia, non-specific ST-T wave changes, or conduction abnormalities secondary to myocarditis or electrolyte shifts. Tourniquet test (petri-plate test) yields >20 petechiae per square inch.
5. Staging, Classification & Clinical Scoring Systems
WHO 2009 Classification: Dengue without Warning Signs
Acute fever plus any 2 criteria: nausea/vomiting, rash, aches/pains, tourniquet test positive, leukopenia; manageable in outpatient settings with oral hydration and strict monitoring.
WHO 2009 Classification: Dengue with Warning Signs
Presence of abdominal pain, persistent vomiting, fluid accumulation, mucosal bleeding, lethargy, liver enlargement >2 cm, or rising haematocrit concurrent with rapid platelet drop; requires immediate hospital admission for intravenous fluid titration.
WHO 2009 Classification: Severe Dengue
Defined by severe plasma leakage leading to shock (DSS) or fluid accumulation with respiratory distress, severe bleeding, or severe organ impairment (AST/ALT $\ge$1000 IU/L, impaired consciousness, or myocarditis); requires emergency intensive care unit admission.
Classic DHF Grading (Grades I–IV)
Grade I: Fever with positive tourniquet test only. Grade II: Grade I plus spontaneous bleeding (skin/mucosal). Grade III: Circulatory failure with rapid, weak pulse, narrow pulse pressure (≤20 mmHg), and hypotension (DSS). Grade IV: Profound shock with undetectable blood pressure and pulse.
6. Differential Diagnosis
Differential Condition
Distinguishing Clinical, Biochemical & Imaging Features
Malaria
Features intermittent high fevers, rigors, prominent splenomegaly, and intraerythrocytic parasites on thick and thin blood smears; lacks the characteristic plasma leakage and hemoconcentration of dengue.
Leptospirosis
Characterized by sudden high fever, severe myalgia predominantly affecting the calves, conjunctival suffusion, and early renal or hepatic dysfunction, often linked to exposure to contaminated water or animal urine.
Meningococcemia / Sepsis
Presents with rapidly progressive purpuric or petechial rash, signs of septic shock, elevated procalcitonin, and positive blood cultures; lacks the classic biphasic defervescence timing of dengue.
Chikungunya / Zika Virus
Marked predominantly by debilitating, prolonged symmetrical polyarthralgias and arthritis (Chikungunya) or mild rash with conjunctivitis and minimal systemic toxicity (Zika); severe plasma leakage and shock are exceedingly rare.
7. Management & Treatment Protocol
Initial Stabilization & Resuscitation: Continuous hemodynamic monitoring of vital signs, hourly urine output, and serial haematocrit estimations. Immediate intravenous access establishment is vital upon identification of warning signs or early shock1, 7.
First-Line Medical / Pharmacological Therapy (with exact adult dosing): Protocolized judicious isotonic crystalloid resuscitation. Initiate infusion of 0.9% Sodium Chloride or Ringer's Lactate at 5–10 mL/kg/h for 1–2 hours in compensated shock, then taper gradually according to clinical response, target urine output of 0.5–1 mL/kg/h, and falling haematocrit1, 7. In cases of refractory shock failing crystalloid boluses (10–20 mL/kg over 15–30 minutes), administer rescue colloids (such as 5% albumin or dextran 40) at 10–20 mL/kg. Strictly avoid non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin due to severe bleeding risks and platelet dysfunction; utilize paracetamol (acetaminophen) for analgesia and antipyresis with adult dosing of 500 mg to 1 g orally every 4–6 hours (maximum 4 g/day).
Surgical / Interventional Indications: Blood component therapy is reserved for active, major bleeding. Transfuse packed red blood cells (5–10 mL/kg) for significant hemorrhage. Prophylactic platelet transfusions are strongly discouraged for asymptomatic thrombocytopenia. Therapeutic paracentesis or thoracentesis is indicated only if large fluid collections cause severe, unyielding respiratory compromise.
8. Complications & Prognosis
Key acute complications include profound hypovolemic shock, acute respiratory distress syndrome (ARDS) secondary to massive fluid overload, disseminated intravascular coagulation (DIC), severe gastrointestinal hemorrhage, acute kidney injury, encephalopathy, and multi-organ dysfunction syndrome1, 3, 6. With timely recognition and protocolized fluid management, mortality from severe dengue remains below 1%, whereas untreated dengue shock syndrome carries a mortality rate exceeding 20%2. Long-term prognosis is excellent, with complete recovery of bone marrow and endothelial function in survivors during the convalescent phase.
🎓 Board Exam Pearls & Clinical Pitfalls
Exam Pearl 1: A rising haematocrit (PCV) of 20% or greater above baseline is the hallmark objective laboratory sign of plasma leakage in dengue haemorrhagic fever, distinguishing it from uncomplicated dengue fever.
Clinical Pitfall 2: Never administer prophylactic platelet transfusions for isolated thrombocytopenia without active bleeding, as it does not prevent hemorrhage and risks volume overload in leaking capillary beds.
Board Pearl 3: The critical phase characteristically occurs around the time of defervescence (typically days 3 to 7 of illness) when the temperature drops, yet this is precisely when vascular permeability peaks and patients are at highest risk for sudden hypovolemic shock.
📚 Verified PubMed & Guideline References (7) — click any reference to open the source